According to a recent study, dermatologists are more likely than other physicians to prescribe standard of care therapies to pediatric hidradenitis suppurativa (HS) patients.
Study shows IL-23 inhibitors linked to lowest risk on paradoxical AD in PsO patients
According to a recent study, IL-23 inhibitors used to treat psoriasis patients are associated with the lowest risk of paradoxical atopic dermatitis (AD) compared to other biologics.
New AD guidelines published with updated treatments and recommendations
The American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force has published updated atopic dermatitis (AD) guidelines based on new available treatments and evidence-based recommendations.
Abrocitinib safe and efficacious in AD patients with or without allergic comorbidities
According to a recent study, abrocitinib is efficacious and well tolerated in atopic dermatitis (AD) patients with or without allergic comorbidities.
Children with AD are more likely to develop non-atopic comorbidities
According to a recent study, children and adolescents with atopic dermatitis (AD) are more likely to develop multiple non-atopic comorbidities than those without AD.
Pruritus, pain are main drivers of AD impact and HRQoL, according to study
According to a recent study, pain and pruritus are the main contributors to atopic dermatitis (AD) burden and poor health-related quality of life (HRQoL).
Study shows PsO patients with pruritis, sleep disturbances experience lower QoL in all domains
According to a recent study, psoriasis (PsO) patients with pruritis and related sleep disturbances showed a lower quality of life in all domains.
Researchers create new tool to predict psoriatic arthritis in psoriasis patients
Researchers developed a tool, called the Psoriatic Arthritis Risk Estimation Tool (PRESTO), using clinical variables to predict psoriatic arthritis (PsA) risk in psoriasis patients with reasonable accuracy.
Study shows patch tests for allergic contact dermatitis still effective in AD patients on dupilumab
According to a recent study, the use of dupilumab in patients with atopic dermatitis (AD) did not significantly affect the results of patch tests for allergic contact dermatitis.
Roflumilast shows efficacy in 95% of plaque psoriasis patients
According to a recent press release, roflumilast showed significant improvement in disease severity in 95% of plaque psoriasis patients by week 8.
HealthMinute.TV 